AR and prostate adenocarcinoma: About 50% of CRPCa cases retain the characteristics of prostate adenocarcinoma (AdPCa), expressing markers associated with the luminal epithelia of the prostate, such as androgen receptor (AR), AR targets, and HOXB132,3.